Category Specific RSS

cystic fibrosis

Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler

Aptar Pharma has deemed now the perfect time to exercise their option to purchase an inventive piece of Pharmaxis’ (ASX:…

3 years ago

Pharmaxis sales thriving in US following FDA approval for cystic fibrosis treatment

The world’s most lucrative healthcare market is quickly appreciating Aussie pharmaceuticals company Pharmaxis (ASX: PXS) whose cystic fibrosis (CF) treatment…

4 years ago